Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 14Recruiting 13Not yet recruiting 11Completed 3Suspended 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer 1

Interventions

Specimen Handling 12Magnetic Resonance Spectroscopy 10Cyclophosphamide 10Cisplatin 7Bevacizumab 7pembrolizumab 6Radiosurgery 6Oxaliplatin 5Nivolumab 5Irinotecan 5Fluorouracil 5Everolimus 5Capecitabine 5Biopsy 5venetoclax 4fludarabine 4S 1 (combination) 4Prednisone 4Leucovorin 4Gemcitabine 4Etoposide 4Drug Therapy 4Doxorubicin 4Azacitidine 4fludarabine phosphate 3Vincristine 3Taxes 3Tacrolimus 3Surveys and Questionnaires 3Surgical Procedures, Operative 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × OTHER × fluzoparib × Clear all
NCT05656131 2026-03-17

Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer

Sun Yat-sen University

Phase 2 Suspended
80 enrolled
Breast

Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡